FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies

Data Compilation
#PharmaFlow

Pipeline Prospector Jan 2025: J&J’s US$ 14.6 bn Intra-Cellular buyout kicks off deal frenzy; Ozempic clinches FDA nod for CKD

Stock Recap
#PipelineProspector

Solprin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

55 API Suppliers, 24 USDMF, 8 CEP/COS, 2 JDMF, 1 EU WC, 2 KDMF, 33 NDC API, 28 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

38 Drugs in Development

38 Drugs in Development

FINISHED DOSAGE FORMULATIONS

455 FDF Dossiers, 117 FDA Orange Book, 110 Europe, 88 Canada, 8 Australia, 24 South Africa, 108 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 356.4MG;30MG;16MG, TABLET;ORAL - 325MG;50MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 325MG;50MG;40MG;30MG, TABLET, DELAYED RELEASE;ORAL - 325MG;40MG, TABLET, DELAYED RELEASE;ORAL - 81MG;40MG, TABLET;ORAL - 250MG;250MG;65MG, CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 325MG;50MG;40MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Minakem, 8 Evonik, 13 Rochem International Inc, 31 SPI Pharma, 2 Seqens, 24 DKSH, 3 Pharm-RX Chemical, 10 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 10 Gangwal Healthcare, 15 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 Capital Farma, 1 Pramukh Pharmachem, 4 ACG Worldwide, 15 Actylis, 2 Aeon Procare, 3 Alcedo Pharmachem, 11 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 40 BASF, 1 Bioplus Life Sciences, 3 Clariant, 15 Corel Pharma Chem, 7 DFE Pharma, 3 Doshion Polyscience, 3 Finar, 16 Gangwal Chemicals, 17 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 40 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 24 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 4 Novo Excipients, 5 Pharmatrans-Sanaq, 12 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 47 Roquette, 19 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 5 Vasa Pharmachem, 1 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

125 Fillers, Diluents & Binders, 91 Coating Systems & Additives, 56 Thickeners and Stabilizers, 53 Solubilizers, 49 Controlled & Modified Release, 46 Taste Masking, 45 Disintegrants & Superdisintegrants, 44 Direct Compression, 38 Parenteral, 37 Granulation, 35 Topical, 34 Film Formers & Plasticizers, 30 Lubricants & Glidants, 26 Chewable & Orodispersible Aids, 18 Co-Processed Excipients, 16 Emulsifying Agents, 14 API Stability Enhancers, 12 Surfactant & Foaming Agents, 11 Rheology Modifiers, 9 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 184 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 70 Finished Drug Prices, 10 Annual Reports

MARKET PLACE

55 APIs, 43 FDF Dossiers

PATENTS & EXCLUSIVITIES

12 US Patents

12 US Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 1 JP, 8 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/01/2025	Adare Pharma Solutions	U.S.A	EURAND AMERICA INC	6586	MICROENCAPSULATED ASPIRIN	1986-02-06	Inactive	II	N/A
28/01/2025	Atabay	Turkey	ATABAY KIMYA SANAYI VE TICARET AS	6268	ASPIRIN 100% (U.S.P.).	1986-04-14	Inactive	II	N/A

Solprin

Solprin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

55 API Suppliers

24 USDMF

8 CEP/COS

2 JDMF

1 EU WC

2 KDMF

33 NDC API

28 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

38 Drugs in Development

FINISHED DOSAGE FORMULATIONS

455 FDF Dossiers

117 FDA Orange Book

110 Europe

88 Canada

8 Australia

24 South Africa

108 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 356.4MG;30MG;16MG

TABLET;ORAL - 325MG;50MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 325MG;50MG;40MG;30MG

TABLET, DELAYED RELEASE;ORAL - 325MG;40MG

TABLET, DELAYED RELEASE;ORAL - 81MG;40MG

TABLET;ORAL - 250MG;250MG;65MG

CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 325MG;50MG;40MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI

2 Minakem

8 Evonik

13 Rochem International Inc

31 SPI Pharma

2 Seqens

24 DKSH

3 Pharm-RX Chemical

10 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

1 Chynops Pharma

10 Gangwal Healthcare

15 Nanjing Well Pharmaceutical

2 Pfanstiehl

1 Capital Farma

1 Pramukh Pharmachem

4 ACG Worldwide

15 Actylis

2 Aeon Procare

3 Alcedo Pharmachem

11 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

40 BASF

1 Bioplus Life Sciences

3 Clariant

15 Corel Pharma Chem

7 DFE Pharma

3 Doshion Polyscience

3 Finar

16 Gangwal Chemicals

17 Ideal Cures Pvt Ltd

5 Ingredion Pharma Solutions

40 Kerry

5 Kima Chemical

6 Lonza Capsugel

24 Microlex e.U

1 Nanjing Bold Chemical

1 NEWEDGE Overseas

2 Nomisma Healthcare

4 Novo Excipients

5 Pharmatrans-Sanaq

12 Pluviaendo

5 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

TABLET;ORAL - 325MG;50MG;40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons